Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Journal of Gynecologic Oncology ; : 269-272, 2010.
Artículo en Inglés | WPRIM | ID: wpr-6889

RESUMEN

Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.


Asunto(s)
Femenino , Humanos , Adenofibroma , Adenosarcoma , Mama , Neoplasias de la Mama , Neoplasias Endometriales , Medición de Riesgo , Tamoxifeno , Toremifeno
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA